{"product_id":"vrca-marketing-mix","title":"(VRCA) Verrica Pharmaceuticals Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Verrica Pharmaceuticals Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page includes a real preview\/sample of the analysis so you can evaluate style and content before buying. Purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH 0.7%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH 0.7% is Verrica Pharmaceuticals Inc.’s lead commercial product and a cantharidin-based topical solution for molluscum contagiosum. It is designed for clinician use in the office, which supports the Product pillar by making treatment simple, fast, and tightly controlled. As the first FDA-approved cantharidin therapy in the U.S., it gives Verrica a clear niche in a market with limited direct branded competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolluscum contagiosum, 2+\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH is Verrica Pharmaceuticals Inc.'s core marketed product for molluscum contagiosum, approved in adults and children 2 years and older, making it a rare pediatric and adult dermatology therapy. In 2025, it remained the company’s lead revenue driver, with FY2025 reporting centered on growing U.S. adoption and repeat use in office-based care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use applicator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.’s single-use applicator is designed for in-office use by a healthcare professional, not as a take-home self-treatment. It delivers a controlled, one-time dose of cantharidin 0.7%, which supports consistent administration and helps reduce dosing variability. The single-use format also fits a clinic workflow, since each application is prepared for one patient visit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVP-103 plantar warts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVP-103 is Verrica Pharmaceuticals Inc.'s cantharidin-based candidate for plantar warts, extending the Company’s wart pipeline beyond its first dermatology focus. Plantar warts are a common, hard-to-treat condition, so success here could widen the market beyond the current wart segment and add another revenue path. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCantharidin-based wart therapy\u003c\/li\u003e\n\u003cli\u003eTargets plantar warts\u003c\/li\u003e\n\u003cli\u003eBroadens Verrica Pharmaceuticals Inc. pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLTX-315 dermatological oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. licenses LTX-315 from Lytix Biopharma, adding a separate dermatological oncology program to its skin-disease mix. The asset is an oncolytic peptide platform for skin cancer use, which broadens Verrica Pharmaceuticals Inc. beyond its core dermatology focus.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Verrica Pharmaceuticals Inc. reported net revenue of $21.5 million, so LTX-315 could matter as a pipeline diversifier rather than a near-term revenue driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed from Lytix Biopharma\u003c\/li\u003e\n\u003cli\u003eDermatological oncology focus\u003c\/li\u003e\n\u003cli\u003eDistinct skin-disease program\u003c\/li\u003e\n\u003cli\u003ePipeline diversification for 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH Drives Verrica’s Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYCANTH 0.7% is Verrica Pharmaceuticals Inc.’s lead Product: an FDA-approved, in-office cantharidin solution for molluscum contagiosum in patients 2 years and older. Its single-use applicator supports precise clinician dosing and fits office workflows. In FY2025, Verrica Pharmaceuticals Inc. reported net revenue of $21.5 million, showing YCANTH’s role as the main commercial driver. VP-103 and LTX-315 extend the Product mix into plantar warts and dermatology oncology.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYCANTH 0.7%\u003c\/td\u003e\n\u003ctd\u003eLead commercial product\u003c\/td\u003e\n\u003ctd\u003e$21.5 million net revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP-103\u003c\/td\u003e\n\u003ctd\u003ePlantar warts candidate\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLTX-315\u003c\/td\u003e\n\u003ctd\u003eSkin-cancer program\u003c\/td\u003e\n\u003ctd\u003eLicensed asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P’s analysis of Verrica Pharmaceuticals Inc. covering product, price, place, and promotion strategy in real market context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSimplifies Verrica Pharmaceuticals’ 4P’s into a clear, at-a-glance summary that reduces analysis overload and speeds decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources—clinical trials, SEC filings, industry reports—to let investors and reviewers verify Verrica's market, pricing, and competitive assumptions quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWest Chester, Pennsylvania\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. is headquartered in West Chester, Pennsylvania, and this 2025 corporate base anchors U.S. management and operations. The location keeps leadership close to the Philadelphia life-sciences corridor, which supports hiring, partners, and day-to-day execution. It is the company’s core U.S. command center.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. keeps its commercial focus in the United States, where YCANTH was launched in the dermatology market and remains the main route to sales and patient access. The U.S. is also the company’s only active commercial place, so every script, payer win, and clinic expansion matters. In 2025 filings, that U.S.-first model stayed tied to specialty dermatology offices, not broad retail distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician office delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH is delivered in healthcare provider offices, which matches Verrica Pharmaceuticals Inc.'s office-based dermatology model and keeps administration under clinical supervision. This setup supports same-visit treatment and fits pediatric and dermatology workflows. It also reduces the need for at-home handling, which can help drive adherence and patient safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty distribution channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. uses specialty healthcare channels, so its products reach physician offices and specialty sites instead of retail shelves. That fits a clinic-administered treatment model, where access, handling, and prescriber oversight matter more than broad consumer distribution. This channel design also supports tighter control of reimbursement and patient flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician-administered access\u003c\/li\u003e\n\u003cli\u003eNot retail shelf sales\u003c\/li\u003e\n\u003cli\u003eMatches clinical use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJapan via Torii\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.’s Japan via Torii channel is a licensed collaboration with Torii Pharmaceutical Co., Ltd. for Japan, giving Verrica a route into the world’s 3rd-largest economy and expanding reach beyond the U.S. This place strategy helps the company localize commercialization without building a full in-country sales force.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJapan rights are held through Torii.\u003c\/li\u003e\n\u003cli\u003eExtends Verrica beyond the U.S.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerrica’s U.S.-First Footprint: Specialty Dermatology, Plus Japan via Torii\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.’s Place is U.S.-centric: West Chester, Pennsylvania anchors management, while YCANTH is sold mainly through specialty dermatology offices. That office-based route keeps treatment under clinician supervision and fits same-visit care. Japan is the main non-U.S. place, accessed through Torii Pharmaceutical Co., Ltd.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eWest Chester, PA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial market\u003c\/td\u003e\n\u003ctd\u003eU.S. only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003eTorii channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eVerrica Pharmaceuticals Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Verrica Pharmaceuticals Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, editable document ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatology sales focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. uses a specialist-to-specialist promotion model, focusing sales calls on dermatologists and skin-care prescribers who treat molluscum contagiosum and warts. That fits the addressable U.S. market: molluscum affects about 6 million people each year, and verrucae (warts) drive millions of office visits, so each prescriber can reach a high-volume patient pool. The message is built for clinicians, not consumers, to support adoption in this niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric HCP education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH’s label covers children 2 years and older, so pediatricians are a core HCP audience for Verrica Pharmaceuticals Inc. Education can improve early recognition of molluscum contagiosum and speed referral to prescribing clinicians. That matters because treatment starts only after diagnosis, and better awareness can lift patient flow into YCANTH.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. promotes clinical data communications by pointing to trial readouts and FDA milestones, especially YCANTH’s 2023 FDA approval for molluscum contagiosum. In CAMP-1 and CAMP-2, complete clearance at day 84 was 46.3% vs 18.0% and 54.8% vs 13.4% for vehicle, giving prescribers a clear efficacy signal. That kind of proof builds trust fast, and it helps support adoption in office-based dermatology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCongresses and press releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals uses congresses and press releases to keep YCANTH and its pipeline visible, a standard play for a small-cap biopharma with 1 marketed product. Since YCANTH became the first and only FDA-approved treatment for molluscum contagiosum in 2023, conference data and company updates help turn clinical news into market awareness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 marketed product: YCANTH\u003c\/li\u003e\n\u003cli\u003eFDA approval: 2023\u003c\/li\u003e\n\u003cli\u003eChannels: congresses, press releases\u003c\/li\u003e\n\u003cli\u003eGoal: product and pipeline awareness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTorii collaboration support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTorii collaboration support gives Verrica Pharmaceuticals Inc. an external commercialization channel in Japan, so promotion can reach doctors through a local partner instead of a direct buildout. Torii can also support local market development, which extends Verrica Pharmaceuticals Inc.’s promotion into a partner-led geography.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJapan sales route runs through Torii\u003c\/li\u003e\n\u003cli\u003eLocal market development stays partner-led\u003c\/li\u003e\n\u003cli\u003ePromotion scales without a full Japan team\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH Gains Traction on Strong HCP-Led Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.'s promotion is HCP-led, aimed at dermatologists and pediatricians for YCANTH, the first FDA-approved molluscum contagiosum treatment in 2023. The core proof point is CAMP-1\/2: complete clearance at day 84 was 46.3% and 54.8% vs 18.0% and 13.4% for vehicle. Congresses, press releases, and Torii in Japan extend reach without a large field force.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYCANTH\u003c\/td\u003e\n\u003ctd\u003eFDA approved 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAMP-1\/2\u003c\/td\u003e\n\u003ctd\u003e46.3%, 54.8% vs vehicle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003eTorii-led promotion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription-only pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYCANTH is a prescription-only dermatology product with 0.1% cantharidin, so its price sits inside physician prescribing and pharmacy benefit coverage, not an OTC shelf model. Because it is billed through medical and pharmacy channels, payer contracts and prior authorization can shape what patients actually pay out of pocket. That makes pricing less about a sticker price and more about reimbursement, access, and office-administered use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffice-administered reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc.'s office-applied treatment is reimbursed through medical billing, so access depends on payer rules, prior auth, and site-of-care policies. For patients, out-of-pocket cost can range from $0 to hundreds of dollars per visit, based on plan design and deductible status. That makes coverage more important than the sticker price. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty channel billing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. uses specialty channel billing for YCANTH, which fits an office-administered drug model. Specialty distribution supports tighter supply control and smoother reimbursement handling, especially for a treatment applied in clinic every 3 weeks for up to 4 sessions. It also helps offices manage prior auth and patient billing with less inventory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess support and prior authorization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerrica Pharmaceuticals Inc. depends on payer approval, so access can slow when prior authorization is required before treatment starts. That matters because prior auth is a major care barrier: the AMA says 94% of physicians reported it delays care, which makes support services a key part of the Price decision.\u003c\/p\u003e\n\u003cp\u003ePatient support programs can help cut friction at the point of care by guiding benefits checks, paperwork, and appeals. For Verrica Pharmaceuticals Inc., that can improve fill rates and reduce abandoned starts when coverage is uncertain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayer approval can gate access.\u003c\/li\u003e\n\u003cli\u003ePrior auth slows treatment starts.\u003c\/li\u003e\n\u003cli\u003eSupport programs reduce friction.\u003c\/li\u003e\n\u003cli\u003eCoverage help can lift uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline assets not commercialized\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVP-103 and LTX-315 have no commercial price yet because Verrica Pharmaceuticals Inc. has not launched either asset as an approved marketed product. Their value is still pipeline-based, so any future price will depend on trial results, FDA approval, and launch terms, not retail pricing today.\u003c\/p\u003e\n\u003cp\u003eThat means current economics are tied to development progress, while Verrica Pharmaceuticals Inc.'s 2025 reported commercial revenue came from YCANTH, not these pipeline assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVP-103: no approved price\u003c\/li\u003e\n\u003cli\u003eLTX-315: no approved price\u003c\/li\u003e\n\u003cli\u003eValue depends on approval\u003c\/li\u003e\n\u003cli\u003eCurrent value is pipeline-based\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYCANTH Pricing Runs on Reimbursement, Not Sticker Price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYCANTH’s price is shaped by payer coverage, prior authorization, and office billing, not an OTC sticker price. In 2025, Verrica Pharmaceuticals Inc.’s commercial revenue came from YCANTH, while VP-103 and LTX-315 still had no approved market price. Patient support matters because the AMA says 94% of physicians report prior auth delays care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003ePrice status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYCANTH\u003c\/td\u003e\n\u003ctd\u003eReimbursed, payer-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVP-103 \/ LTX-315\u003c\/td\u003e\n\u003ctd\u003eNo approved price yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior auth\u003c\/td\u003e\n\u003ctd\u003e94% report delays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235141525769,"sku":"vrca-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vrca-marketing-mix.webp?v=1785735556","url":"https:\/\/dcfanalyst.com\/products\/vrca-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}